aripiprazole / Generic mfg. - LARVOL DELTA

Disproportionality signal for myopia associated with aripiprazole: Analysis of the FAERS database and review of the literature. (PubMed, Schizophr Res) - No abstract available

Journal • CNS Disorders • Ophthalmology

Long-term treatment with lithium, valproate, and atypical antipsychotics on suicide risk in patients with bipolar disorder: A nationwide retrospective cohort study. (PubMed, J Affect Disord) - "Suicide risk decreased during treatment with lithium or valproate alone. In patients with bipolar disorder who are at a high risk of suicide, atypical antipsychotics may be associated with a reduced risk of suicide when combined with lithium and valproate."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

A screen to identify antifungal antagonists reveals a variety of pharmacotherapies that induce echinocandin tolerance in Candida albicans. (PubMed, Antimicrob Agents Chemother) - "More detailed evaluation of five such drugs, including the atypical antipsychotic aripiprazole and the tyrosine kinase inhibitor ponatinib, indicated they promote C. albicans survival following exposure to the echinocandin antifungals. Thus, the echinocandin antagonistic drugs modulate C. albicans physiology in ways that could impact its pathogenicity and/or response to therapeutic intervention. Finally, a mutant lacking the Efg1p transcription factor, which has a central role in the activation of C. albicans hyphal growth, was found to have intrinsically high levels of echinocandin tolerance, suggesting a link between modulation of morphogenesis-related signaling and echinocandin tolerance."

Journal • CNS Disorders

Real-World Disability Outcomes Among Patients Treated with Cariprazine vs Other Atypical Antipsychotics as Adjunctive Treatment for Major Depressive Disorder. (PubMed, Clinicoecon Outcomes Res) - "In this real-world analysis of patients with MDD using AAs adjunctively to antidepressants, significantly greater reductions were observed in disability claims and days for cariprazine vs brexpiprazole and in disability costs for cariprazine vs aripiprazole. These results suggest that adjunctive cariprazine may have beneficial effects on disability outcomes for patients with MDD."

Journal • Real-world evidence • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Selective recognition memory impairment in mitochondrial hydroxylase Clk1 mutant mice, rescued by antipsychotics. (PubMed, Acta Pharmacol Sin) - "Recent evidence shows that Clk1+/- mutant mice are resistant to morphine- and methamphetamine-induced conditioned place preference. Administration of antipsychotic drugs aripiprazole (0.3 mg·kg-1·d-1, i.p.) or risperidone (1 mg·kg-1·d-1, i.p.) for 7 days fully rescued Clk1 mutation-induced recognition memory deficits. This study provides primary evidence highlighting the role of mitochondrial Clk1 in the regulation of recognition memory and presents an informative model for investigating mitochondrial function in learning and memory."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CLK1

The Impact of Adjunctive Aripiprazole on Olanzapine-Induced Metabolic Adverse Effects in Patients With Schizophrenia: A Systematic Review. (PubMed, Neuropsychopharmacol Rep) - "Adjunctive aripiprazole had variable effects on metabolic parameters in patients on olanzapine therapy; however, reductions in triglycerides appeared consistent among most of the data, and some studies reported significant weight loss. This highlighted that aripiprazole does have some effect in reducing metabolic adverse effects caused by olanzapine."

Adverse events • Journal • Review • CNS Disorders • Diabetes • Dyslipidemia • Psychiatry • Schizophrenia

Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databases. (PubMed, Ther Adv Psychopharmacol) - "In this observational study, incidence rates of EPS-related events, defined as the first dispensing of an anticholinergic drug during follow-up, were compatible with the known safety profile of AOM but showed substantial regional variation. EU PAS number EUPAS21056."

Journal • CNS Disorders • Diabetes • Metabolic Disorders

Aripiprazole (Abilify) as a new treatment for circadian rhythm sleep-wake disorders (CRSWDs) and its mechanism of action (WSS 2025) - "A meta-analysis confirmed that aripiprazole is highly effective as a treatment option for CRSWDs. It was also confirmed that the mechanism of action is a direct effect on SCN. Melatonin as a therapeutic drug promotes sleep onset, but aripiprazole promotes early awakening, so it is expected that its effectiveness will be enhanced by using it in combination."

Delayed Sleep Phase Disorder • Sleep Disorder • Sleep Wake Cycle Disorder

Aripiprazole treatment for post-COVID-19 sleep duration prolongation (WSS 2025) - No abstract available

Infectious Disease • Novel Coronavirus Disease

Point of Care Apps for Facilitating Guideline Uptake by Clinicians (WFSBP 2025) - " The preference-based tool incorporates ten first-line interventions—aripiprazole, asenapine, cariprazine, divalproate, lamotrigine, lithium, lurasidone, paliperidone, quetiapine, and risperidone—and evaluates them against 17 safety outcomes... This point-of-care app provides a promising solution to the challenges of implementing evidence-based clinical guidelines in BD care. By incorporating patient preferences and utilizing multicriteria decision analysis, the tool enhances treatment adherence, fosters personalized care, and improves clinical outcomes. It offers a more accessible and tailored approach to BD management, benefiting both clinicians and patients in everyday practice."

Clinical • Bipolar Disorder • CNS Disorders • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder

Should Dopamine Receptor Partial Agonist Antipsychotics (DRPA) Be co-Administered? - Similarities and Differences (WFSBP 2025) - " A comparative review of pharmacodynamic and -kinetic properties of the three DRPAs – aripiprazole (ARI), brexpiprazole (BREX) and cariprazine (CAR) – was done based on literature (2-4). From a pharmacodynamic perspective, the combination of DRPAs to enhance antipsychotic efficacy is not supported, because their mechanism of action is similar and not complementary. They also overlap with respect to pharmacokinetic characteristics, although CAR is the longest acting. Better combinations with DRPAs may be the -pines (clozapine, quetiapine, olanzapine) (1)."

CNS Disorders • Psychiatry • Schizophrenia

Glutamate Modulation as Adjunctive Therapy in Patients with Schizophrenia Not Adequately Responding to Second-Generation antipsychotics: Clinical Benefits of Evenamide in a Phase 2/3, international, randomized, double-Blind, Placebo-Controlled Trial (WFSBP 2025) - "Patients were randomized 1:1 to receive evenamide 30 mg bid or placebo bid added to a stable therapeutic dose of one of the following SGA: aripiprazole, cariprazine, clozapine, quetiapine, olanzapine, paliperidone, or risperidone. Study 008A represents the first randomized, placebo-controlled trial to demonstrate statistically significant and clinically meaningful benefits of adding a glutamate modulator in patients with schizophrenia poorly responding to treatment with SGAs. A phase 3 trial with evenamide will determine the benefits of glutamate modulation in TRS."

Clinical • Late-breaking abstract • P2/3 data • CNS Disorders • Epilepsy • Psychiatry • Schizophrenia

Glutamate Modulation as Adjunctive Therapy in Patients with Schizophrenia Not Adequately Responding to Second-Generation antipsychotics: Clinical Benefits of Evenamide in a Phase 2/3, international, randomized, double-Blind, Placebo-Controlled Trial (WFSBP 2025) - "Patients were randomized 1:1 to receive evenamide 30 mg bid or placebo bid added to a stable therapeutic dose of one of the following SGA: aripiprazole, cariprazine, clozapine, quetiapine, olanzapine, paliperidone, or risperidone. Study 008A represents the first randomized, placebo-controlled trial to demonstrate statistically significant and clinically meaningful benefits of adding a glutamate modulator in patients with schizophrenia poorly responding to treatment with SGAs. A phase 3 trial with evenamide will determine the benefits of glutamate modulation in TRS."

Clinical • P2/3 data • CNS Disorders • Epilepsy • Psychiatry • Schizophrenia

A Simulation-Based Analysis of Clinical Data to Assess Pharmacodynamic Interaction Effects of Augmentation Agents with Clozapine in Treatment-Resistant Schizophrenia (WFSBP 2025) - "Clozapine augmentation showed antagonistic effects with risperidone and ziprasidone but additive effects with haloperidol, aripiprazole, and quetiapine. Augmenting clozapine with ECT may enhance its antipsychotic efficacy. While some antipsychotics, such as aripiprazole, exhibit additive effects, their potential to increase adverse effects warrants careful consideration."

Clinical data • PK/PD data • CNS Disorders • Psychiatry • Schizophrenia • AFF3

Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis. (PubMed, CNS Drugs) - "The prolactin-increasing property varies among antipsychotics, is dose-related, and is greater in females. These findings in adults with acutely exacerbated schizophrenia can help clinicians titrate and adapt antipsychotic doses and consider patients' sex in treatment decisions. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO); registration no. CRD42020181467."

Journal • Retrospective data • Review • CNS Disorders • Psychiatry • Schizophrenia

Late-Onset Oral Cenesthopathy With Dopaminergic Dysfunction: Therapeutic Response to Pramipexole in a Case With Suspected Prodromal Lewy Body Disease. (PubMed, Psychogeriatrics) - "As antidepressant augmentation, low-dose aripiprazole improved both mood and oral symptoms, but oversedation and parkinsonism necessitated tapering and discontinuation. Overall, the presentation was conceptually compatible with the psychiatric-onset phenotype described in the prodromal Lewy body disease research framework, but this remains an interpretive consideration rather than a diagnosis. Assessing possible dopaminergic involvement in similar cases of oral cenesthopathy may aid individualised management; however, the therapeutic role of dopamine agonists requires confirmation in prospective studies."

Journal • Anesthesia • CNS Disorders • Depression • Lewy Body Disease • Movement Disorders • Parkinson's Disease • Psychiatry

Closing the Evidence Gap: Retrospective and Prospective Strategies to Advance Aripiprazole's Potential Benefits in Patients With Cancer. (PubMed, Pharmacol Res Perspect) - No abstract available

Journal • Retrospective data • Oncology

A Severe Case of Drug-Induced Hypersensitivity Syndrome (DIHS) Presenting as Acute Liver Failure Requiring Urgent Liver Transplantation (ACG 2025) - "He was recently initiated aripiprazole and oral diclofenac 3 week prior.Initial labs showed AST 2687, ALT 1810, total bilirubin 14.8, INR 1.5 and renal failure...While eosinophilia is a hallmark feature, it may be absent initially in up to 31% of cases. This case emphasizes the need for early recognition of DIHS and the potential for severe outcomes requiring liver transplantation.Figure: Liver core needle biopsy demonstrating portal inflammation with bridging necrosis extending along the interface with the lobular parenchyma (H+E stain, 20X).Figure: Liver explant, demonstrating extensive inflammation and nodularity imparted by extensive bridging necrosis (H+E stain, 4X)"

Clinical • CNS Disorders • Eosinophilia • Fatigue • Hepatology • Immunology • Inflammation • Liver Failure • Musculoskeletal Pain • Renal Disease • Transplantation

Posttraumatic Stress Disorder Psychopharmacology Algorithm Update-2024-2025. (PubMed, Psychiatry Clin Psychopharmacol) - "Prazosin remains the first-line treatment for PTSD-related sleep impairment, including nightmares and disturbed awakenings, and it may be useful for individuals with comorbid alcohol use disorder and comorbid headaches. After treating PTSD insomnia, if significant daytime symptoms remain, a selective serotonin reuptake inhibitor ( SSRI, sertraline or paroxetine are suggested), and this may be augmented by an antipsychotic (consider aripiprazole first) if psychotic symptoms, if any, do not respond to the SSRI...This update also evaluates emerging treatments, including transcranial magnetic stimulation, direct current stimulation, stellate ganglion block, and pimavanserin, though concluding that current evidence does not yet warrant their inclusion in the core algorithm. This update provides clinicians with an evidenceinformed approach to pharmacological PTSD management based on the latest available data."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Insomnia • Mood Disorders • Pain • Post-traumatic Stress Disorder • Sleep Disorder

Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents. (PubMed, Pharmaceutics) - "Clinical data, including drug concentrations (AD: fluoxetine, mirtazapine, (es)citalopram, sertraline; AP: aripiprazole, quetiapine, olanzapine, risperidone), were collected using an internet-based registry, and treatment outcomes and ADEs were assessed during routine visits. Our findings suggest that sex may not affect serum levels of investigated AD and AP in children/adolescents. However, treatment outcome of fluoxetine was associated with sex, with higher probability for a better outcome in female patients diagnosed with mood (affective) disorders."

Journal • ADHD (Impulsive Aggression) • Anorexia • Autism Spectrum Disorder • CNS Disorders • Depression • Genetic Disorders • Psychiatry

Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics. (PubMed, Int J Obes (Lond)) - "Semaglutide and tirzepatide induce weight loss among those prescribed SGAs, with lower effectiveness in those prescribed higher AIWG SGAs."

Journal • CNS Disorders • Diabetes • Metabolic Disorders

Better treatment outcomes with aripiprazole long-acting injection in community and incarcerated patients with serious mental illness. (PubMed, Front Psychiatry) - "Both groups experienced reduced hospitalizations and improvements in CGI-S scores and quality of life following aripiprazole LAI administration. Community patients showed a greater reduction in hospitalizations, while clinical and quality-of-life improvements were comparable across groups."

Journal • CNS Disorders • Mood Disorders • Personality Disorder • Psychiatry • Schizophrenia

Successful antipsychotic dose tapering leading to better cognition in patients with remitted psychosis: Results of Guided Antipsychotic Reduction to Reach Minimum Effective Dose (GARMED) trial. (PubMed, Psychol Med) - "Lowering antipsychotic dosage may ameliorate patient performance in several cognitive domains. This finding is worthy of consideration while evaluating the risk-to-benefit ratio of tapering antipsychotics in patients with remitted psychosis."

Journal • CNS Disorders • Psychiatry • Schizophrenia

All Twenty Nails Affected: Aripiprazole-Induced Photo-Onycholysis in an 11-Year-Old Boy. (PubMed, Cureus) - "The patient was managed with topical anti-inflammatories, vinegar soaks, and strict photoprotection, and was referred for dermatologic and podiatric follow-up. This case emphasizes the need for awareness of nail phototoxicity associated with atypical antipsychotics and the importance of prompt recognition to avoid unnecessary interventions."

Journal • CNS Disorders • Dermatology • Pediatrics

Treatment of Early-Onset Specified and Unspecified Bipolar Disorders: A Systematic Review and Strategies for Identifying and Managing a Thermally Dysregulated Subtype in Children. (PubMed, Acta Psychiatr Scand) - "Good support was provided in the 11 studies for the use of adjunctive family-focused psychotherapeutic approaches, and this approach should be considered an important part of any treatment regimen. The pharmacological treatment landscape for S-USBD lacks a systematic research base, warranting further exploration with controlled clinical trials. Case series indicate promising treatment outcomes for TSDD with high-dose lithium, clonidine, ketamine, and other cooling measures. Validation of this novel treatment strategy in controlled trials is needed to advance the management of the S-USBD variants."

Clinical • Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry